Home > Dermatology > EADV 2022 > Nalbuphine: another candidate for an approved treatment in prurigo nodularis?

Nalbuphine: another candidate for an approved treatment in prurigo nodularis?

Presented By
Prof. Sonja Ständer, University Medical Centre of Münster, Germany
Conference
EADV 2022
Trial
Phase 3, PRISM
The results of the PRISM trial on prurigo nodularis (PN) were positive regarding all endpoints: Significantly more patients on nalbuphine achieved at least a 4-point decrease on the worst itch (WI-) numeric rating scale (NRS), quality-of-life (QoL) rose, and skin lesions improved. As currently approved pharmacologic therapies for PN are still lacking, results of the phase 2b/3 PRISM trial (NCT03497975) were eagerly awaited. The trial investigated nalbuphine, a dual κ-opioid receptor agonist/µ-opioid receptor antagonist as treatment for pruritus in PN [1]. Of note, abuse and addiction potential in activation of the κ-opioid receptor was found to be very low to non-existent. Included were 353 patients, randomised to receive either placebo or 162 mg of oral nalbuphine in an extended-release formulation, twice daily, after a 2-week titration. The baselin...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on